Inflexion
Menu

CNX Therapeutics

In 2021 Inflexion acquired CNX Therapeutics, a European pharmaceutical company dedicated to the supply of essential medicines. The business was formed when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion.

Shutterstock 1892170054

  • Sector

    Healthcare

  • Headquarters

    London, UK

  • Fund

    Buyout

  • Investment date

    August 2021

  • Status

    Current

The company

CNX Therapeutics is a European pharmaceutical company dedicated to the supply of essential medicines with a portfolio of speciality brands and hospital products.

The business was formed in August 2021 when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion. The carve out included the pan-European licensing rights to a patent-protected medicine used for the treatment of schizophrenia.

The Inflexion difference

With substantial experience in successfully executing carve-outs, Inflexion is drawing on its healthcare expertise to establish CNX Therapeutics as a standalone business. We are supporting CNX Therapeutics to build its product portfolio to develop a scaled European platform. This will focus heavily on hospital and central nervous system therapies that stand to benefit from its existing infrastructure and capabilities.